In MM, selective JAK1 inhibitor INCB052793 in combination with carfilzomib, bortezomib, dexamethasone or lenalidomide effectively reduced tumor volume in tumor-bearing mice [159]; another novel and orally available JAK1/2 inhibitor, CYT387, was able to prevent IL-6-induced STAT3 phosphorylation and was synergized in killing myeloma cells with traditional therapies Melphalan and Bortezomib [160]. The gene discussed is IL6; the disease is plasma cell myeloma.